This FDA Approval Is Actually a Big Deal: Dendreon Corporation (DNDN)

Page 2 of 2

Another factor to consider is that antibody payload/drug-conjugate technology (depending on whether you’re an ImmunoGen or Seattle Genetics, Inc. (NASDAQ:SGEN) fan) is a new and largely untapped combination therapy. I’ve long felt one of the smartest ways to tackle the drug sector is to focus on companies that develop combination therapies because they create steady and diverse royalty streams and become instant buyout candidates for struggling big pharmas. Aside from Kadcyla, Seattle Genetics’ Adcetris is the only other FDA-approved drug that works along the same delivery pathway, and its success thus far has been limited. With Kadcyla’s approval all momentum swung to ImmunoGen’s side of the fence — especially considering how many clinical combo trials are still under way with Kadcyla.

Not to inflate ImmunoGen’s ego or anything, but it’s kind of a big deal; and I’m predicting that in due time it’ll be an even bigger deal, either through additional indications for Kadcyla or perhaps a buyout by Roche (which I’ve long said would be foolish not to snatch up ImmunoGen).

The article This FDA Approval Is Actually a Big Deal originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool owns shares of Dendreon. Motley Fool newsletter services have recommended buying shares of ImmunoGen.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2